Overview of treatment emergent adverse event (TEAE) per 100 patient-years (PY) by year (intent-to-treat population).
| ADA Exposure Year | N | PY | SAE | Serious Infection | Any Malignancy | AE Leading to Death |
|---|---|---|---|---|---|---|
| 1 | 697 | 643.7 | 21.4 | 2.0 | 0.8 | 0.2 |
| 2 | 581 | 539.4 | 15.8 | 2.4 | 1.9 | 0.7 |
| 3 | 507 | 464.3 | 25.6 | 3.9 | 2.2 | 0.4 |
| 4 | 442 | 421.1 | 19.7 | 1.4 | 3.1 | 0 |
| 5 | 403 | 384.4 | 23.7 | 3.9 | 1.6 | 1.6 |
| 6 | 367 | 348.8 | 16.9 | 1.7 | 3.7 | 0.3 |
| 7 | 334 | 319.6 | 12.8 | 2.2 | 1.6 | 0.3 |
| 8 | 305 | 289.4 | 16.2 | 1.7 | 2.4 | 0 |
| 9 | 275 | 202.2 | 15.3 | 3.0 | 3.0 | 1.5 |
| 10 | 182 | 176.5 | 17.0 | 4.0 | 4.0 | 0 |
| Overall | 697 | 3708.3 | 18.0 | 2.6 | 2.2 | 0.6 |
ADA: adalimumab; SAE: severe adverse event; AE: adverse event.